Five hospitals in Dayton, Ohio have collaborated in the formation of the Dayton Clinical Oncology Program (DCOP). This NCI Community Clinical Oncology Program (CCOP) involves all major institutions within Dayton's defined population area with a history of community collaboration efforts in medical program development and in the cancer field. The DCOP has been able, in a short period of time, to mobilize the resources of its institutional components and health care professionals to initiate development of a more sophisticated cancer program.
DCOP specific aims and objectives include: greater involvement in clinical research at the community level; establishment of a strong organizational structure to support and govern the program development of a data management plan with a high level of quality control that will assure the NCI of superior data for program evaluation; establishment of standards of physician performance; development of pharmacy procedures assuring the NCI, FDA and other agencies of control over investigational agents; and greater involvement of the medical community in cancer control activities, especially physician and nursing patient management guidelines. To accomplish the primary goal of increased involvement in clinical research, the DCOP has provided the following methodology: development of criteria/policies for protocol selection; mechanisms for NCI's evaluation of the diffusion hypothesis, including development of patient log forms with provision of additional data through the computerized data system; establishment of data management responsibilities; design of a data mangement plan; procedures for data maintenance, quality control and transmission to the research bases; and policies for use of investigational drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035090-08
Application #
3557452
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-15
Project End
1995-05-31
Budget Start
1991-06-01
Budget End
1992-05-31
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Kettering Medical Center
Department
Type
DUNS #
City
Kettering
State
OH
Country
United States
Zip Code
45429
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8

Showing the most recent 10 out of 201 publications